ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tktom	12/11/2015 12:00:21 PM
	Read Replies (1) of 4474

Looks like zero chance of a buy out now. This is a small company and the value to another company would clearly be known by now. Now we know the revenue recognition from France will be missed. Should be the most despised biotech in 2015. A 600 patient trial that is really a waste of funds, that they do not have. Insures an equity raise at the end of 2016. The institutions will figure that out. The only news worthy event will be the new CEO. There are a number of new CML compounds in late stage trial (that also treat the T318i mutation) that will essentially take Iclusig off the market when approved. All in all, a real disaster since 1991.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next